Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IP Nivolumab After Surgery and HIPEC in Advanced Ovarian Carcinoma
NCT03959761Phase 2Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Oct 2019
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in ovarian cancer, sponsored by Hospices Civils de Lyon. Primary endpoint: Safety profile of the Intraperitoneal (IP) nivolumab treatment at 28 days. Started Oct 2019; status: completed.
02
Drugs
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03959761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03959761.